Foot-and-Mouth Disease: Optimization, Reproducibility, and Scalability of High-Yield Production of Virus-Like Particles for a Next-Generation Vaccine

Inactivated Foot-and-Mouth Disease (FMD) vaccine has proven to be effective in the control of the disease. However, its production has some disadvantages, including the costly biosafety facilities required for the production of huge amounts of growing live virus, the need of an exhaustive purificat...

Descripción completa

Detalles Bibliográficos
Autores principales: Mignaqui, Ana Clara, Ferella, Alejandra, Cass, Brian, Mukankurayija, Larissa, L’Abbé, Denis, Bisson, Louis, Sánchez, Cintia, Scian, Romina, Cardillo, Sabrina Beatriz, Durocher, Yves, Wigdorovitz, Andres
Formato: Artículo
Lenguaje:Inglés
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:http://hdl.handle.net/20.500.12123/8502
https://www.frontiersin.org/articles/10.3389/fvets.2020.00601/full
https://doi.org/10.3389/fvets.2020.00601
_version_ 1855484212044365824
author Mignaqui, Ana Clara
Ferella, Alejandra
Cass, Brian
Mukankurayija, Larissa
L’Abbé, Denis
Bisson, Louis
Sánchez, Cintia
Scian, Romina
Cardillo, Sabrina Beatriz
Durocher, Yves
Wigdorovitz, Andres
author_browse Bisson, Louis
Cardillo, Sabrina Beatriz
Cass, Brian
Durocher, Yves
Ferella, Alejandra
L’Abbé, Denis
Mignaqui, Ana Clara
Mukankurayija, Larissa
Scian, Romina
Sánchez, Cintia
Wigdorovitz, Andres
author_facet Mignaqui, Ana Clara
Ferella, Alejandra
Cass, Brian
Mukankurayija, Larissa
L’Abbé, Denis
Bisson, Louis
Sánchez, Cintia
Scian, Romina
Cardillo, Sabrina Beatriz
Durocher, Yves
Wigdorovitz, Andres
author_sort Mignaqui, Ana Clara
collection INTA Digital
description Inactivated Foot-and-Mouth Disease (FMD) vaccine has proven to be effective in the control of the disease. However, its production has some disadvantages, including the costly biosafety facilities required for the production of huge amounts of growing live virus, the need of an exhaustive purification process to eliminate non-structural proteins of the virus in the final formulations in order to differentiate infected from vaccinated animals and variable local regulatory restrictions to produce and commercialize the vaccine. Thus, a novel vaccine against FMD that overcome these restrictions is desirable. Although many developments have been made in this regard, most of them failed in terms of efficacy or when considering their transferability to the industry. We have previously reported the use of transient gene expression in mammalian cells to produce FMD virus-like particles (VLPs) as a novel vaccine for FMD and demonstrated the immunogenicity of the recombinant structures in animal models. Here, we report the optimization of the production system by assaying different DNA:polyethylenimine concentrations, cell densities, and direct and indirect protocols of transfection. Also, we evaluated the reproducibility and scalability of the technology to produce high yields of recombinant VLPs in a cost-effective and scalable system compatible with industrial tech-transfer of an effective and safe vaccine.
format Artículo
id INTA8502
institution Instituto Nacional de Tecnología Agropecuaria (INTA -Argentina)
language Inglés
publishDate 2020
publishDateRange 2020
publishDateSort 2020
publisher Frontiers Media S.A.
publisherStr Frontiers Media S.A.
record_format dspace
spelling INTA85022020-12-28T16:58:36Z Foot-and-Mouth Disease: Optimization, Reproducibility, and Scalability of High-Yield Production of Virus-Like Particles for a Next-Generation Vaccine Mignaqui, Ana Clara Ferella, Alejandra Cass, Brian Mukankurayija, Larissa L’Abbé, Denis Bisson, Louis Sánchez, Cintia Scian, Romina Cardillo, Sabrina Beatriz Durocher, Yves Wigdorovitz, Andres Vacuna Inactivada Fiebre Aftosa Enfermedades de los Animales Inactivated Vaccines Foot and Mouth Disease Animal Diseases Inactivated Foot-and-Mouth Disease (FMD) vaccine has proven to be effective in the control of the disease. However, its production has some disadvantages, including the costly biosafety facilities required for the production of huge amounts of growing live virus, the need of an exhaustive purification process to eliminate non-structural proteins of the virus in the final formulations in order to differentiate infected from vaccinated animals and variable local regulatory restrictions to produce and commercialize the vaccine. Thus, a novel vaccine against FMD that overcome these restrictions is desirable. Although many developments have been made in this regard, most of them failed in terms of efficacy or when considering their transferability to the industry. We have previously reported the use of transient gene expression in mammalian cells to produce FMD virus-like particles (VLPs) as a novel vaccine for FMD and demonstrated the immunogenicity of the recombinant structures in animal models. Here, we report the optimization of the production system by assaying different DNA:polyethylenimine concentrations, cell densities, and direct and indirect protocols of transfection. Also, we evaluated the reproducibility and scalability of the technology to produce high yields of recombinant VLPs in a cost-effective and scalable system compatible with industrial tech-transfer of an effective and safe vaccine. Estación Experimental Agropecuaria Bariloche Fil: Mignaqui, Ana Clara. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Bariloche. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Instituto de Investigaciones Forestales y Agropecuarias Bariloche; Argentina Fil: Ferella, Alejandra. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina Fil: Cass, Brian. Human Health Therapeutics Research Center, National Research Council Canada; Canadá Fil Mukankurayija, Larissa. Human Health Therapeutics Research Center, National Research Council Canada; Canadá Fil: L’Abbé, Denis. Human Health Therapeutics Research Center, National Research Council Canada; Canadá Fil: Bisson, Louis. Human Health Therapeutics Research Center, National Research Council Canada; Canada Fil: Sánchez, Cintia. Biogénesis-Bagó; Argentina Fil: Scian, Romina. Biogénesis-Bagó; Argentina Fil: Cardillo, Sabrina Beatriz. Biogénesis-Bagó; Argentina Fil: Durocher, Yves. Human Health Therapeutics Research Center, National Research Council Canada; Canadá Fil: Wigdorovitz, Andres. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina 2020-12-28T16:45:30Z 2020-12-28T16:45:30Z 2020-09 info:ar-repo/semantics/artículo info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/20.500.12123/8502 https://www.frontiersin.org/articles/10.3389/fvets.2020.00601/full 2297-1769 https://doi.org/10.3389/fvets.2020.00601 eng info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by-nc-sa/4.0/ Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) application/pdf Frontiers Media S.A. Frontiers in Veterinary Science 7 : art. 601 (2020)
spellingShingle Vacuna Inactivada
Fiebre Aftosa
Enfermedades de los Animales
Inactivated Vaccines
Foot and Mouth Disease
Animal Diseases
Mignaqui, Ana Clara
Ferella, Alejandra
Cass, Brian
Mukankurayija, Larissa
L’Abbé, Denis
Bisson, Louis
Sánchez, Cintia
Scian, Romina
Cardillo, Sabrina Beatriz
Durocher, Yves
Wigdorovitz, Andres
Foot-and-Mouth Disease: Optimization, Reproducibility, and Scalability of High-Yield Production of Virus-Like Particles for a Next-Generation Vaccine
title Foot-and-Mouth Disease: Optimization, Reproducibility, and Scalability of High-Yield Production of Virus-Like Particles for a Next-Generation Vaccine
title_full Foot-and-Mouth Disease: Optimization, Reproducibility, and Scalability of High-Yield Production of Virus-Like Particles for a Next-Generation Vaccine
title_fullStr Foot-and-Mouth Disease: Optimization, Reproducibility, and Scalability of High-Yield Production of Virus-Like Particles for a Next-Generation Vaccine
title_full_unstemmed Foot-and-Mouth Disease: Optimization, Reproducibility, and Scalability of High-Yield Production of Virus-Like Particles for a Next-Generation Vaccine
title_short Foot-and-Mouth Disease: Optimization, Reproducibility, and Scalability of High-Yield Production of Virus-Like Particles for a Next-Generation Vaccine
title_sort foot and mouth disease optimization reproducibility and scalability of high yield production of virus like particles for a next generation vaccine
topic Vacuna Inactivada
Fiebre Aftosa
Enfermedades de los Animales
Inactivated Vaccines
Foot and Mouth Disease
Animal Diseases
url http://hdl.handle.net/20.500.12123/8502
https://www.frontiersin.org/articles/10.3389/fvets.2020.00601/full
https://doi.org/10.3389/fvets.2020.00601
work_keys_str_mv AT mignaquianaclara footandmouthdiseaseoptimizationreproducibilityandscalabilityofhighyieldproductionofviruslikeparticlesforanextgenerationvaccine
AT ferellaalejandra footandmouthdiseaseoptimizationreproducibilityandscalabilityofhighyieldproductionofviruslikeparticlesforanextgenerationvaccine
AT cassbrian footandmouthdiseaseoptimizationreproducibilityandscalabilityofhighyieldproductionofviruslikeparticlesforanextgenerationvaccine
AT mukankurayijalarissa footandmouthdiseaseoptimizationreproducibilityandscalabilityofhighyieldproductionofviruslikeparticlesforanextgenerationvaccine
AT labbedenis footandmouthdiseaseoptimizationreproducibilityandscalabilityofhighyieldproductionofviruslikeparticlesforanextgenerationvaccine
AT bissonlouis footandmouthdiseaseoptimizationreproducibilityandscalabilityofhighyieldproductionofviruslikeparticlesforanextgenerationvaccine
AT sanchezcintia footandmouthdiseaseoptimizationreproducibilityandscalabilityofhighyieldproductionofviruslikeparticlesforanextgenerationvaccine
AT scianromina footandmouthdiseaseoptimizationreproducibilityandscalabilityofhighyieldproductionofviruslikeparticlesforanextgenerationvaccine
AT cardillosabrinabeatriz footandmouthdiseaseoptimizationreproducibilityandscalabilityofhighyieldproductionofviruslikeparticlesforanextgenerationvaccine
AT durocheryves footandmouthdiseaseoptimizationreproducibilityandscalabilityofhighyieldproductionofviruslikeparticlesforanextgenerationvaccine
AT wigdorovitzandres footandmouthdiseaseoptimizationreproducibilityandscalabilityofhighyieldproductionofviruslikeparticlesforanextgenerationvaccine